港股異動 | 康龍化成漲近6%,寧波大分子公司正在籌劃股權融資,預計融資金額不超過3億美元
$康龍化成(03759.HK)$盤中漲近6%,截至發稿,漲5.52%,報46.85港元,成交額近1億港元。
消息面上,康龍化成公告,公司全資子公司康龍化成(寧波)生物醫藥有限公司(簡稱“寧波大分子公司”)目前正在籌劃以增資擴股方式進行股權融資,預計融資金額不超過3億美元,具體交易對手方目前尚未確定,其中可能包括公司的關聯方/關連人士。
據悉,該事項旨在進一步加快大分子藥物及細胞與基因治療等研發服務能力的建設,提高大分子和細胞與基因治療服務板塊的運營能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.